BioStock: Aptahem's new CRD brings clinical experience to Phase I

Aptahem, whose primary drug candidate Apta-1 is being developed as an acute treatment for sepsis, recently announced that it is expanding its team with Suzanne Kilany as Clinical Research Director. The recruitment comes as the company prepares to move into clinical development with its main candidate. Kilany, who most recently comes from a position as Medical Scientific Adviser (MSA) at Astellas Pharma, is also a long-time board member of the Swedish Pharmaceutical Society’s clinical studies department. Here, she tells BioStock more about her new role at Aptahem. 

 Read the full interview with Suzanne Kilany at biostock.se:

https://www.biostock.se/en/aptahems-new-crd-brings-clinical-experience-to-phase-i/

 This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Subscribe

Quick facts

BioStock: Aptahem's new CRD brings clinical experience to Phase I
Tweet this

Quotes

The goal is to attract a licensing partner after completing phase I/II in order to continue the development. An alternative scenario is to find a partner before entering clinical studies, based on a precise development plan
Suzanne Kilany, CRD Aptahem